Transient receptor potential ankyrin-1 participates in visceral hyperalgesia following experimental colitis.
Transient receptor potential ankyrin-1 (TRPA1) is an important receptor that contributes to inflammatory pain. However, previous studies were mainly concerned with its function in somatic hyperalgesia while few referred to visceral, especially colonic inflammatory hyperalgesia. The present study was aimed to investigate the role of TRPA1 in visceral hyperalgesia after trinitrobenzene sulfonic acid (TNBS)-induced colitis. Results indicate that TNBS induced a significant increase in visceral sensitivity to colonic distension and chemical irritation accompanied by up-regulation of TRPA1 in colonic afferent dorsal root ganglia (DRG). Intrathecal administration of TRPA1 antisense (AS) oligodeoxynucleotide (ODN) reduced the TRPA1 expression in DRG as well as suppressed the colitis-induced hyperalgesia to nociceptive colonic distension and intracolonic allyl isothiocyanate (AITC). Meanwhile the TRPA1 antisense ODN had no effect on transient receptor potential vanilloid-1 (TRPV1) expression, which was proposed to highly co-express with TRPA1, and no effect on the response to TRPV1 agonist, capsaicin. These data suggest an apparent role of TRPA1 in visceral hyperalgesia following colitis that might provide a novel therapeutic target for the relief of pain.
Yang
Jing
J
Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China. liyangqing@sdu.edu.cn
Li
Yanqing
Y
Zuo
Xiuli
X
Zhen
Yanbo
Y
Yu
Yanbo
Y
Gao
Lijun
L
D000818:Animals; D017487:Ankyrins; D015220:Calcium Channels / Q000378:metabolism*; D003092:Colitis / Q000139:chemically induced / Q000150:complications*; D003106:Colon / Q000187:drug effects / Q000378:metabolism; D004195:Disease Models, Animal; D004576:Electromyography; D005769:Gastrointestinal Motility / Q000187:drug effects; D006930:Hyperalgesia / Q000145:classification / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism*; D008297:Male; D020319:Oligodeoxyribonucleotides, Antisense / Q000627:therapeutic use; D010147:Pain Measurement / Q000379:methods; D017288:Pain Threshold / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D013268:Stimulation, Chemical; D000074025:TRPA1 Cation Channel; D050052:TRPC Cation Channels; D050916:TRPV Cation Channels / Q000378:metabolism; D014302:Trinitrobenzenesulfonic Acid; D015854:Up-Regulation / Q000187:drug effects / Q000502:physiology; D017833:Visceral Afferents / Q000187:drug effects / Q000378:metabolism*
D017487:Ankyrins; D015220:Calcium Channels; D020319:Oligodeoxyribonucleotides, Antisense; D000074025:TRPA1 Cation Channel; D050052:TRPC Cation Channels; D050916:TRPV Cation Channels; C480976:Trpa1 protein, rat; C493922:Trpv1 protein, rat; D014302:Trinitrobenzenesulfonic Acid